Shopping Cart 0
Cart Subtotal
AED 0

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018'; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 7 molecules.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The report 'Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018' outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Women's Health which include indications Alzheimer's Disease, Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peripheral T-Cell Lymphomas (PTCL), Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Cancer Pain, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Epithelial Ovarian Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Ovarian Cancer, Parkinson's Disease, Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Psychosis, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Companies Involved in Therapeutics Development

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

Nexus BioPharma Inc

ValiRx Plc

Zen-Bio Inc

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Drug Profiles

dasatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment

Oct 17, 2018: Valirx Val201 enters the concluding stages of its phase l/ll clinical trial

Oct 08, 2018: AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS

Sep 06, 2018: VALIRX: Update on clinical development of VAL201 compound

Aug 30, 2018: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Jul 23, 2018: AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer

Jul 17, 2018: US patent grant for therapeutic compound, VAL301

Jul 05, 2018: BMS' Sprycel secures European nod to treat Ph+ CML

May 28, 2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis

May 15, 2018: EMA Recommends a New Formulation and Extension of Indications for Dasatinib

Apr 25, 2018: ValiRx Announces EU Patent Grant For Therapeutic Compound, VAL201Completes Wide Global Coverage For Therapeutic Use

Apr 19, 2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis

Mar 22, 2018: EPFL: Attacking lymphoma at the source

Mar 20, 2018: Us Patent Grant For Therapeutic Compound, VAL201

Jan 11, 2018: US Patent Notice Of Allowance For Therapeutic Compound, VAL201

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AB Science SA, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Nexus BioPharma Inc, H2 2018

Pipeline by ValiRx Plc, H2 2018

Pipeline by Zen-Bio Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline Assessment


Companies

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

Nexus BioPharma Inc

ValiRx Plc

Zen-Bio Inc

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018'; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 7 molecules.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The report 'Tyrosine Protein Kinase Fyn-Pipeline Review, H2 2018' outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Women's Health which include indications Alzheimer's Disease, Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peripheral T-Cell Lymphomas (PTCL), Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Cancer Pain, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Epithelial Ovarian Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Ovarian Cancer, Parkinson's Disease, Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Psychosis, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Companies Involved in Therapeutics Development

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

Nexus BioPharma Inc

ValiRx Plc

Zen-Bio Inc

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Drug Profiles

dasatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment

Oct 17, 2018: Valirx Val201 enters the concluding stages of its phase l/ll clinical trial

Oct 08, 2018: AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS

Sep 06, 2018: VALIRX: Update on clinical development of VAL201 compound

Aug 30, 2018: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Jul 23, 2018: AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer

Jul 17, 2018: US patent grant for therapeutic compound, VAL301

Jul 05, 2018: BMS' Sprycel secures European nod to treat Ph+ CML

May 28, 2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis

May 15, 2018: EMA Recommends a New Formulation and Extension of Indications for Dasatinib

Apr 25, 2018: ValiRx Announces EU Patent Grant For Therapeutic Compound, VAL201Completes Wide Global Coverage For Therapeutic Use

Apr 19, 2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis

Mar 22, 2018: EPFL: Attacking lymphoma at the source

Mar 20, 2018: Us Patent Grant For Therapeutic Compound, VAL201

Jan 11, 2018: US Patent Notice Of Allowance For Therapeutic Compound, VAL201

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AB Science SA, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Nexus BioPharma Inc, H2 2018

Pipeline by ValiRx Plc, H2 2018

Pipeline by Zen-Bio Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline Assessment


Companies

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

Nexus BioPharma Inc

ValiRx Plc

Zen-Bio Inc